ProfileGDS5678 / 1419132_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 92% 92% 95% 93% 95% 94% 94% 94% 88% 91% 90% 91% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.2673291
GSM967853U87-EV human glioblastoma xenograft - Control 27.6275892
GSM967854U87-EV human glioblastoma xenograft - Control 37.6589592
GSM967855U87-EV human glioblastoma xenograft - Control 48.7255995
GSM967856U87-EV human glioblastoma xenograft - Control 57.9435193
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.3520295
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.9643594
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.1212394
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.0709894
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8859488
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.4601891
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.2676190
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.5093791
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.6376192